Sorafenib: Drug Summary |
|
Name |
Sorafenib |
Chemical formula |
C21H16CIF3N4O3 |
Chemical structure |
 |
Administration route |
Oral |
Dosage |
400 mg b.i.d. |
Indication |
2005: FDA approval for advanced renal cell carcinoma.
2006: Marketing authorization given by the European Commission for renal cell carcinoma.
2007: Marketing authorization given by the European Commission for hepatocellular carcinoma;
FDA approval for hepatocellular carcinoma. |
|